Phase II study of oral S‐1 for treatment of metastatic colorectal carcinoma

@article{Shirao2004PhaseIS,
  title={Phase II study of oral S‐1 for treatment of metastatic colorectal carcinoma},
  author={K. Shirao and A. Ohtsu and H. Takada and Y. Mitachi and K. Hirakawa and N. Horikoshi and T. Okamura and K. Hirata and S. Saitoh and H. Isomoto and A. Satoh},
  journal={Cancer},
  year={2004},
  volume={100}
}
The goal of the current study was to evaluate the objective response rate and toxicity associated with the oral fluoropyrimidine S‐1 (a combination of tegafur, 5‐chloro‐2,4‐dihydroxypyridine, and potassium oxonate) in patients with previously untreated metastatic colorectal carcinoma. 
Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer.
  • H. Choi, N. Kim, +9 authors J. Ahn
  • Medicine
  • Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 2008
TLDR
A phase I trial to establish a schedule of S-1/irinotecan with standard pelvic radiotherapy as a preoperative treatment of locally advanced rectal cancer suggests that this new combination is feasible and well tolerable. Expand
An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma
TLDR
S-1 is active and well tolerated for the treatment of cytokine-refractory metastatic RCC and should be continued until disease progression, unacceptable toxicity, or withdrawal of consent. Expand
A late phase II study of S-1 for metastatic pancreatic cancer
TLDR
The major adverse events were anorexia, fatigue, hemoglobin reduction, nausea and pigmentation change, although most were tolerable and reversible and the condition resolved with anticoagulant therapy. Expand
Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer
TLDR
SOX regimen is effective and easily manageable without central vein access, and major grade 3 or 4 adverse reactions at the RD were neutropaenia, thrombocytopaenIA, and diarrhoea. Expand
A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix
TLDR
SOX therapy is useful for the treatment of recurrent adenocarcinoma of the uterine cervix, having a promising antitumor effect and minimal adverse effects, and it is suggested that SOX therapy may contribute to improving the prognosis. Expand
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer
  • W. Koizumi, N. Boku, +9 authors Y. Okada
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2010
TLDR
S-1 combined with LV therapy demonstrated promising efficacy and acceptable safety in chemotherapy-naive patients with mCRC without the concurrent use of irinotecan, oxaliplatin, or molecular-targeted drugs. Expand
Phase II study of S‐1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off
TLDR
A phase II study of S‐1 plus leucovorin given in a 4‐week schedule for patients with untreated metastatic colorectal cancer showed that the combination was effective, but grade 3 toxicities occurred at a relatively high rate. Expand
Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
TLDR
Oral S-1 and concurrent radiotherapy exerted a promising antitumor activity with acceptable toxicity in patients with locally advanced pancreatic cancer and seems to be an attractive alternative to conventional chemoradiotherapy using 5-fluorouracil infusion. Expand
A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer
TLDR
The SOLA therapy showed excellent efficacy and tolerable toxicities except for peripheral sensory neuropathy in patients with mCRC, and is a promising candidate regimen to be compared with FOLFOX plus bevacizumab in a future phase III trial. Expand
Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.
  • A. Goto, Y. Yamada, +5 authors K. Shirao
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2006
TLDR
It is suggested that combined treatment with S-1 and irinotecan is a promising regimen, offering benefits in terms of safety and survival as compared with conventional regimens in patients with advanced colorectal cancer. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma
TLDR
It is suggested that S-1 achieves similar responses to those of infusional 5-FU plus leucovorin and shows the potential of another biochemical modulation with easily manageable toxicity. Expand
Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer
TLDR
This oral treatment is suitable for outpatients because of its mild toxicity and further therapeutic benefits are likely to be obtained by combining S-1 with other chemotherapeutic agents. Expand
[Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer].
TLDR
S-1 was considered to be an active single agent against NSCLC and performed well in patients receiving initial chemotherapy for unresectable, advanced non-small-cell lung cancer. Expand
Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.
TLDR
S-1 is effective against advanced gastric cancer and this oral treatment is suitable for outpatients because of its mild toxicity and further therapeutic benefits are likely to be obtained by combining S-1 with other chemotherapeutic agents. Expand
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).
TLDR
S-1 can be administered with an acceptable safety and toxicity in European patients at a dose of 35 mg/m(2) days 1 - 28 every 5 weeks and is associated with a moderate response rate similar to the results achieved with other fluoropyrimidines. Expand
An Early Phase II Study of Oral S-1, a Newly Developed 5-Fluorouracil Derivative for Advanced and Recurrent Gastrointestinal Cancers
TLDR
The antineoplastic effect of S-1, an antitumor agent developed, based on the biochemical modulation of FT by 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo), in a molar ratio of 1:0.4:1 is considered to have positive effects in patients with advanced gastrointestinal cancer. Expand
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer
TLDR
S-1 is active in advanced colorectal cancer, but in order to establish a safer dose the drug should be subject to further investigations, and the dose was reduced by amendment during the study because of a higher than expected number of severe adverse drug reactions. Expand
[Late phase II study of S-1 in patients with advanced head and neck cancer].
TLDR
It is concluded that S-1 is an active agent for the treatment of advanced/recurrent head and neck cancer. Expand
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
TLDR
S-1 may improve patients' quality of life because the pharmacokinetics of orally administered S-1 is almost similar to that of continuous i.v. infusion of 5-FU, it is concluded. Expand
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
TLDR
A review of the literature on three recent prodrugs of 5-FU, i.e., capecitabine, UFT (ftorafur [FTO] plus uracil), and S-1 (FTO plus 5-chloro-2,4-dihydroxypyridine plus potassium oxonate), focusing on antitumor activity and toxicity are presented. Expand
...
1
2
3
4
5
...